Free Trial
Your Rate Never Goes Up! Save $100 a Year on MarketBeat All Access
Upgrade Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:OABI

OmniAb Q3 2026 Earnings Date & Estimates

OmniAb logo
$4.78 -0.13 (-2.65%)
Closing price 10/22/2026 04:00 PM Eastern
Extended Trading
$4.75 -0.03 (-0.67%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OmniAb is scheduled to report Q3 2026 earnings on Friday, October 30, 2026, after market closes. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from OmniAb in Q3 2026

OmniAb is expected to post earnings of -$0.12 per share on revenue of $3.49 million. In the same quarter a year earlier OmniAb reported -$0.14 per share on revenue of $2.24 million. OmniAb last reported on August 6, 2026, posting -$0.05 per share and beating the -$0.12 consensus estimate. OmniAb has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.12
Expected Revenue
$3.49 million
Prior-Year EPS
-$0.14
Prior-Year Revenue
$2.24 million
Expected Revenue Growth
+56.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.05 (Beat by +$0.07)
Last Quarter Revenue
$13.42 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

OmniAb Q3 2026 Earnings FAQ

OmniAb (NASDAQ:OABI) has confirmed it will report Q3 2026 earnings on Friday, October 30, 2026, after market closes.

OmniAb's Q3 2026 earnings conference call is scheduled for Friday, October 30, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect OmniAb to post earnings of -$0.12 per share for Q3 2026.

The consensus revenue estimate for OmniAb is $3.49 million for Q3 2026.

OmniAb Earnings Headlines

OmniAb (OABI) Projected to Release Quarterly Earnings on Friday
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31148246
OmniAb to Report Third Quarter 2026 Financial Results on October 30
October 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261014742993/en/omniab-to-report-third-quarter-2026-financial-results-on-october-30/
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
 |  Base Camp Trading (Ad)
Reviewing Illumina (NASDAQ:ILMN) & OmniAb (NASDAQ:OABI)
October 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31114279
OmniAb, Inc. (OABI) Analyst/Investor Day Transcript
October 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4952316-omniab-inc-oabi-analyst-investor-day-transcript
OmniAb, Inc. (OABI) Analyst/Investor Day - Slideshow
October 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4952328-omniab-inc-oabi-analyst-investor-day-slideshow
See More OmniAb Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OmniAb? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OmniAb and other key companies, straight to your email.

About OmniAb

OmniAb (NASDAQ:OABI) is a biotechnology company that develops and licenses antibody discovery technologies for use in drug research and development. Its platform is designed to help biopharmaceutical companies generate fully human and species-diverse antibodies that can be evaluated as potential treatments for a range of diseases.

The company’s technology portfolio includes genetically engineered animal platforms, such as OmniRat, OmniMouse and OmniChicken, which are used to produce antibody candidates against challenging biological targets. OmniAb also provides related discovery capabilities and works with partners to identify and advance antibody-based therapeutics, including conventional monoclonal antibodies and other engineered antibody formats.

OmniAb was established as an independent public company in 2022 after being separated from Ligand Pharmaceuticals. The company serves biotechnology and pharmaceutical partners internationally through research collaborations, licensing arrangements and other strategic relationships. Its business model is centered on enabling partner drug programs rather than primarily commercializing its own portfolio of marketed medicines.

View OmniAb Profile
Earnings Tools